Top

World Journal of Urology

Published in:

01-08-2014 | Original Article

¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer

Authors: H. Kjölhede, G. Ahlgren, H. Almquist, F. Liedberg, K. Lyttkens, T. Ohlsson, O. Bratt

Published in: World Journal of Urology | Issue 4/2014

Abstract

Purpose

To compare ¹⁸F-fluorocholine positron-emission tomography/computed tomography (PET/CT) with extended pelvic lymph node dissection (ePLND) for the detection of lymph node metastases in a large cohort of patients with high-risk prostate cancer.

Materials and methods

Patients with prostate-specific antigen levels between 20 and 99 ng/mL and/or Gleason score 8–10 cancers, planned for treatment with curative intent following a negative or inconclusive standard bone scan, were investigated with ¹⁸F-fluorocholine PET/CT followed by an ePLND. None of the patients received hormonal therapy prior to these staging procedures. Results for PET/CT were compared on a per-patient basis with histopathology from ePLND. Sensitivity, specificity, positive and negative predictive values were calculated.

Results

PET/CT detected a total of 76 suspected lymph node metastases and four suspected bone metastases in 33 (29 %) of the 112 included patients. Of these, 35 suspected lymph node metastases, only within the anatomical template area of an ePLND, were found in 21 of the patients. Histopathology of the ePLND specimens detected 117 lymph node metastases in 48 (43 %) of the 112 patients. Per-patient sensitivity, specificity, positive and negative predictive values for ¹⁸F-fluorocholine PET/CT for lymph node metastases within the ePLND template were 0.33, 0.92, 0.76 and 0.65, respectively. Only 11 patients had lymph nodes larger than 10 mm that would have been reported by CT alone.

Conclusions

¹⁸F-fluorocholine PET/CT detects lymph node metastases in a significant proportion of patients with high-risk prostate cancer with a high specificity, but low sensitivity.

Available only for authorised users

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71PubMedCrossRef

Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37PubMedCrossRef

Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395PubMedCrossRef

Heesakkers RA, Hövels AM, Jager GJ, Van Den Bosch HC, Witjes JA, Raat HP et al (2008) MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9(9):850–856PubMedCrossRef

Giannarini G, Petralia G, Thoeny HC (2012) Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 61(2):326–340PubMedCrossRef

Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD (2002) Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate cancer prostatic dis 5(2):132–135PubMedCrossRef

Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen W-D, Brelin A et al (2011) Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 81(1):29–34PubMedCrossRef

Häcker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W et al (2006) Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [¹⁸F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176(5):2014–2018 (discussion 2018–2019)PubMedCrossRef

Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF et al (2010) [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 46(2):449–455PubMedCrossRef

10.

Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F et al (2010) ¹⁸F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254(3):925–933PubMedCrossRef

11.

De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44(3):331–335PubMed

12.

Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A et al (2008) Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35(2):253–263PubMedCrossRef

13.

Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, et al. (2010) [¹⁸F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 106:639–643; discussion 644

14.

Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A et al (2008) 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54(2):392–401PubMedCrossRef

15.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T et al (2012) Combined ¹⁸F-fluorocholine and ¹⁸F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 110(10):1501–1506PubMedCrossRef

16.

Kryza D, Tadino V, Filannino MA, Villeret G, Lemoucheux L (2008) Fully automated [¹⁸F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nucl Med Biol 35(2):255–260PubMedCrossRef

17.

Schillaci O, Calabria F, Tavolozza M, Cicciò C, Carlani M, Caracciolo CR et al (2010) ¹⁸F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 31(1):39–45PubMedCrossRef

18.

Gil-Vernet JM (1996) Prostate cancer: anatomical and surgical considerations. Br J Urol 78(2):161–168PubMedCrossRef

19.

Meijer HJM, van Lin EN, Debats O a, Witjes JA, Span PN, Kaanders JH a M et al (2011) High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 82(4):1405–1410

20.

Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53(1):118–125PubMedCrossRef

21.

Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166(5):1715–1719PubMedCrossRef

22.

Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate—to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048PubMedCrossRef

23.

Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S et al (2011) Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol 29(5):595–605PubMedCrossRef

Title: 18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer
Authors: H. Kjölhede
G. Ahlgren
H. Almquist
F. Liedberg
K. Lyttkens
T. Ohlsson
O. Bratt
Publication date: 01-08-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 4/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1189-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

¹⁸F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

Expression of aquaporin water channels in human urothelial carcinoma: correlation of AQP3 expression with tumour grade and stage

Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy

Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation

Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer

Can we predict the clinical outcomes of genitourinary trauma patients and offer them an evidence-based support? The case for telemedicine network

DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomy